Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphonoacetaldehyde hydrolase is a bacterial enzyme that catalyzes the hydrolysis of phosphonoacetaldehyde to acetaldehyde and phosphate, breaking a stable carbon-phosphorus (C-P) bond. It plays a key role in the metabolism of organophosphonates, particularly as part of the 2-aminoethylphosphonate degradation pathway in certain microorganisms such as Bacillus cereus. The enzyme acts via a mechanism involving imine (Schiff base) formation with a lysine residue in the active site, labilizing the C-P bond. It requires magnesium as a cofactor and belongs to the haloacid dehalogenase (HAD) superfamily. There are no known drugs targeting this bacterial enzyme, and it is not considered a therapeutic target in humans. Its primary biological relevance is in microbial phosphorus metabolism rather than direct clinical implications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphonoacetaldehyde hydrolase.